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BACKGROUND: Because sunitinib can induce extensive necrosis in metastatic renal cell cancer (mRCC), we examined whether criteria
defined by Choi might be valuable to predict early sunitinib efficacy.
METHODS: Computed tomography was used for measurement of tumour lesions in mm and lesion attenuation in Hounsfield units
(HUs). According to Choi criteria partial response (PR) was defined as X10% decrease in size or X15% decrease in attenuation.
RESULTS: A total of 55 mRCC patients treated with sunitinib were included. At first evaluation, according to the Response Evaluation
Criteria in Solid Tumours (RECIST) 7 patients had PR, 38 stable disease (SD), and 10 progressive disease (PD), whereas according to
Choi criteria 36 patients had PR, 6 SD and 13 PD. Median tumour attenuation decreased from 66 to 47 HUs (Pp0.001). In patients
with PR, Choi criteria had a significantly better predictive value for progression-free survival and overall survival (both Pso0.001) than
RECIST (P¼0.685 and 0.191 respectively). The predictive value for RECIST increased (P¼0.001 and o0.001 respectively), when
best response during treatment was taken into account.
CONCLUSION: Choi criteria could be helpful to define early mRCC patients who benefit from sunitinib, but the use of these criteria will
not change the management of these patients.
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The Response Evaluation Criteria in Solid Tumours (RECIST) is
the most widely used measurement system in clinical trials and is
based on the sum of the longest diameters of the appointed target
lesions in the transversal plane (Therasse et al, 2000). Clinically
meaningful responses, however, may be underestimated by
RECIST, as new targeted therapies can cause tumour necrosis
without a marked decrease in tumour size (Faivre et al, 2007). The
receptor tyrosine kinase inhibitors (TKIs) imatinib, sunitinib,
sorafenib, and axitinib are known to cause early and extensive
necrosis (Vanel et al, 2005; Faivre et al, 2007; Flaherty, 2007; Rixe
et al, 2007; Van der Veldt et al, 2008b). Treatment-induced
necrosis, however, is not a part of RECIST and may even mimic
progressive disease (PD).
In hepatocellular carcinoma (HCC), RECIST may be inappro-
priate as primary end point to evaluate sunitinib treatment (Faivre
et al, 2007). Therefore, Faivre et al (2007) have used volumetric
measurements for sunitinib-induced necrosis in HCC expressed
as minor (o50%) and major (¼50%) post-treatment tumour
necrosis. As RECIST also underestimates imatinib-induced
responses in gastrointestinal stromal cell tumours (GISTs), Choi
et al (2007) have developed new response criteria to evaluate
imatinib treatment in patients with GIST. These criteria include
changes in tumour attenuation on computed tomography (CT),
which reflect tumour density (Benjamin et al, 2007; Choi et al,
2007). Choi et al (2007) have defined a partial response (PR) as a
X10% decrease in one-dimensional tumour size or a X15%
decrease in tumour attenuation on CT scan, whereas PD was
defined as X10% increase in size without meeting PR criteria by
change in attenuation (Table 1). The Choi criteria correlated better
with disease-specific survival in imatinib-treated GIST patients
than RECIST.
Several studies have indicated that sunitinib can induce necrosis
in metastatic renal cell cancer (mRCC; Motzer et al, 2006; Baccala
et al, 2007; Van der Veldt et al, 2008b). During sunitinib treatment,
responding RCC lesions can be observed with dramatic decrease in
attenuation, but little change in size. Although sunitinib has shown
PR in 31% of patients in the first-line setting (Motzer et al, 2007), it
remains unclear if RECIST optimally predicts treatment outcome
and if new response criteria are required. Because the beneficial
effect of anti-angiogenic agents in mRCC may also be stabilisation
rather than substantial tumour regression in a large number of
patients, the one-dimensional RECIST for PR, a X30% decrease
in the sum of the longest diameter of target lesions, may be
inaccurate in the TKI era (Van Cruijsen et al, 2008). Because
Choi criteria (Choi et al, 2007) may also be of value to evaluate
tumour responses in tumours other than GIST, such as RCC
and HCC, treated with targeted agents, we here compared the
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susefulness of Choi criteria with RECIST in sunitinib-treated
mRCC patients.
PATIENTS AND METHODS
Patients and treatment
Medical records of patients were reviewed who were treated with
sunitinib for advanced RCC in two centres in the Netherlands (VU
University Medical Center and The Netherlands Cancer Institute)
from December 2005 to October 2007. Most patients had been
included in an expanded access programme (EAP) (Van der Veldt
et al, 2008a) until September 2006 after which sunitinib was
registered and available on doctor’s prescription. In the EAP, each
participant signed a protocol-specific informed consent approved
by the institutional review board in accordance with national and
institutional guidelines. For further analysis of CT scans according
to Choi criteria, adequate safeguards to protect patient privacy
were maintained.
Sunitinib was administered orally at a dose of 50mg daily,
consisting of 4 weeks of treatment followed by a 2-week rest period in
cycles of 6 weeks. A dose reduction of sunitinib (to 37.5 or 25mg) was
allowed depending on the type and severity of adverse events. If
patients had symptoms of PD during the rest period, there was the
possibility for continuous dosing of sunitinib at 37.5mg per day.
For evaluation of sunitinib efficacy, CT scans were performed at
baseline and during treatment to assess clinical response according to
RECIST version 1.0 (Therasse et al,2 0 0 0 ) .F o rR E C I S T ,b e s tr e s p o n s e
was also determined on subsequent CT scans during treatment.
Progression-free survival (PFS) was the time between the first day of
sunitinib treatment and the date of PD on the CT scan according to
RECIST, clear clinical evidence of PD, or death due to PD within 12
weeks after the last response evaluation. If a patient had not
progressed, PFS was censored at the time of the last follow-up. If the
PD date was unknown or a patient died due to PD later than 12 weeks
after the last response evaluation, PFS was censored at the last
adequate tumour assessment. Overall survival (OS) was the time
between the first day of treatment and the date of death or the date at
which a patient was last known to be alive. For PFS and OS analyses,
data collection was closed on 1 September 2009.
Image analysis
Patients were eligible for inclusion in the analysis, if they had CT
scans at baseline and at first evaluation according to the same scan
protocol in the same hospital and at least one tumour lesion at
baseline 415mm. Patients with bone metastasis (n¼2) or
primary tumour (n¼1) as only evaluable lesion were excluded.
Primary tumours were also excluded, as the overall response may
be underestimated due to their enormous size (Van der Veldt et al,
2008b; Bex et al, 2009). Furthermore, brain (Helgason et al, 2008)
and bone metastases at baseline were excluded.
Routine helical CT scans of the thorax and abdomen were
obtained with a scanning delay of 30 and 70s after start of
intravenous (i.v.) injection of a low-osmolar non-ionic contrast
agent (Omnipaque 300 (nycomed Amersham plc, Buckinghamshire,
England) or Ultravist 300 (Bayer Shenng Pharma, Berlin, Germany)).
For abdominal scans, Choi criteria were applied in the portal
venous phase of contrast. All series were reconstructed in 5mm
contiguous axial slices. Scans were shown at standard soft tissue
kernel and window (window centre, 20 Hounsfield units (HUs);
window width, 360 HU) to avoid pixel averages from surrounding
lung parenchyma. Image viewing and manipulation were con-
trolled with Centricity RA 600 version 6.1 software (GE Healthcare
Inc., Wauwatosa, WI, USA), which allows the radiologist to draw
perimeters around the regions of interest. The software then
automatically calculates the area enclosed by the perimeter and the
mean attenuation of this area in HU. A specialised radiologist
(MRM, 7 years of experience in radiology) masked to clinical
history and patients’ outcome and experienced in using the image
viewing and manipulation software examined the CT scan images
in the presence of a junior researcher (AAM vdV). To draw
comparable perimeters over the tumours, we analysed CT scans at
baseline and evaluation from one patient in the same session.
Between the two observers, agreement on identification and
delineation of the lesions was obtained in all cases. In addition,
to evaluate the intra-observer variability for the determination of
tumour attenuation, reproducibility of placing regions of interest
over tumours was tested on 2 different days (43 months between
the measurements). As to the intra-observer variability for tumour
attenuation measurements, Spearman’s correlation coefficients
were rX0.957 (P40.001) for the HU value of individual lesions as
well as the mean HU value in the individual patients.
For each patient, a maximum of 10 delineated tumour target
lesions were identified (not more than 5 per organ). For RECIST
measurements, the longest diameter of the tumour lesions was
X10mm, whereas for Choi criteria the diameter was X15mm
(Table 1; Choi et al, 2007). The attenuation on CT (density) of lesions
X15mm was determined in HUs by drawing a region of interest
around the margin of the entire tumour. Then, the tumour
attenuation assessments of all lesions were combined and a mean
attenuation on CT was computed for each patient. Thereafter, the
percentage of change in attenuation from the pretreatment scan to
the first evaluation during sunitinib was calculated for each patient.
Statistics
Statistical analysis was performed using SPSS software (SPSS for
Windows 15.0, SPSS Inc., Chicago, IL, USA). For testing possible
correlations, the Spearman’s correlation test was performed. The
Wilcoxon’s signed-ranks test was used to compare the changes in size
and attenuation at baseline and at first evaluation. A two-tailed
probability value of Po0.05 was considered significant. For the
analyses according to RECIST and Choi criteria, patients were
categorised into response (CRþPR) vs no response (SDþPD). For
RECIST, patients were also classified as having clinical benefit
(CRþPR and SDX12 weeks) vs no clinical benefit (SDo12 weeks
and PD). PFS and OS were calculated with the Kaplan–Meier method.
Log-rank test was used to test the differences between survival curves.
RESULTS
Patients
A total of 55 mRCC patients treated with sunitinib were included
in this study, of which 45 patients were participants in an EAP
Table 1 Choi response criteria (Choi et al, 2007)
Response Definition
CR Disappearance of all lesions
No new lesions
PR A decrease in size X10% or a decrease in tumour attenuation
(HU) X15% on CT
No new lesions
No obvious progression of non-measurable disease
SD Does not meet criteria for CR, PR, or PD
No symptomatic deterioration attributed to tumour
progression
PD An increase in tumour size X10% and does not meet criteria of
PR by tumour attenuation on CT
New lesions
Abbreviations: CR¼complete response; PR¼partial response; SD¼stable disease;
PD¼progressive disease; HU¼Hounsfield unit.
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sof sunitinib. One patient was excluded due to evident differences in
phases of i.v. contrast between the two subsequent CT scans.
Table 2 presents the patients’ characteristics. The median age
was 59 years (range: 20–81 years). Of 55, 48 patients had clear
cell histology. Of 55 patients, 40 patients were cytokine-pretreated
of whom 4 patients were also pretreated with other anti-angiogenic
agents. The median time from the baseline CT scan and
the initiation of sunitinib treatment was 0.5 months (range:
0–1.5 months). The median time from the start of sunitinib to the
CT scan for first evaluation was 1.9 months (range: 1.1–3.4
months).
Response according to RECIST
For RECIST measurements, 225 tumour lesions were eligible. At
first evaluation these lesions showed a median change in tumour
size of  10% (range:  100 to þ189%). Seven (13%) patients
reached PR, 38 (69%) patients stable disease (SD), and 10 (18%)
patients PD, resulting in 7 responders and 48 non-responders. Five
out of ten patients with PD were categorised as PD based on the
occurrence of new lesions, including two patients with sympto-
matic brain metastases. Ten (18%) patients had SD at first
evaluation, but reached a PR at later time points (median time to
PR: 3.9 months; range: 2.4–9.7 months), resulting in an overall PR
rate of 31%. A total of 24 patients had SDX12 weeks as best
response.
Table 3 Tumour lesions for the efficacy analysis in patients with mRCC
treated with sunitinib
N
Eligible lesions for analysis
RECIST 225
Choi criteria 173
Exclusion according to both RECIST and Choi criteria 26
Bone metastasis 11
Primary tumour 10
Brain metastasis 5
Exclusion according to Choi criteria only 52
10mmptumour lesion at baseline o15mm 38
Air-containing cavity at evaluation 8
Beam-hardening artefact obscuring helical CT density
(e.g. metal-containing parts)
6
Abbreviations: RECIST¼Response Evaluation Criteria in Solid Tumours;
CT¼computed tomography.
Table 2 Patient characteristics
Total N¼55
Variable N (%)
Sex
Male 34 (62)
Female 21 (38)
Median age, years (range) 59 (20–81)
ECOG performance status
0 24 (43)
1 22 (40)
2 5 (9)
3 2 (4)
Unknown 2 (4)
Tumour type
Clear cell 48 (87)
Other 7 (13)
Previous nephrectomy 45 (82)
Prior treatment
None 15 (27)
Cytokine based-therapy 40 (73)
Anti-angiogenic therapy 4 (7)
No. of disease sites
1 7(13)
2 20 (36)
X3 28 (51)
Sites of disease
Lung 49 (89)
Lymph nodes 32 (58)
Bone 13 (24)
Liver 11 (20)
Local recurrence 7 (13)
Brain 4 (7)
MSKCC risk groups
a
0 (favourable) 11 (20)
1–2 (intermediate) 36 (65)
X3 (poor) 7 (13)
Unknown 1 (2)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; MSKCC¼Memorial
Sloan-Kettering Cancer Center.
aRisk groups according to MSKCC prognostic criteria
(based on the 5 risk factors: low Karnofsky performance status (o80%), high LDH
(41.5 times the upper limit of normal), low serum haemoglobin, high corrected
serum calcium (410mg per 100ml), and time from initial diagnosis to treatment of
less than 1 year) (Motzer et al, 2002).
Figure 1 An example of a renal cell cancer patient with lung metastases at baseline (A) and pulmonary cavitations at first evaluation during sunitinib
(B, arrow). For the purpose of illustration the lung window setting is shown.
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sResponse according to Choi criteria
For Choi criteria, less tumour lesions were eligible than for RECIST
(Table 3; Figure 1), namely 173. Lesions most frequently excluded
from the analysis had a tumour size o15mm before treatment
(n¼38). In 24 lesions the change in tumour attenuation could not
be determined due to a tumour size o15mm at evaluation. At
baseline, the median tumour size was 26mm (range: 15–140mm)
for all lesions, with a median attenuation of 66 HUs (range: 6–135
HUs). During sunitinib at first evaluation, the median size
and attenuation had decreased to, respectively, 24mm (range:
0–186mm; Wilcoxon’s signed-ranks test, Pp0.001) and 47 HUs
(range: 4–112 HUs; Pp0.001). A significant decrease in attenua-
tion was measured at all tumour sites (Table 4; Figure 2).
Preliminary analysis did not show a significant difference in the
change in attenuation between the seven patients with non-clear
cell histology and the 48 patients with clear cell histology. Overall,
a weak correlation was calculated between the percentage of
change in tumour size and the percentage of change in attenuation
(Spearman’s r¼0.187, P¼0.022).
At first evaluation according to Choi criteria, 36 (65%) patients
reached PR, 6 (11%) had SD, and 13 (24%) had PD, resulting in 36
responders and 19 non-responders. Of 38, 29 patients who were
categorised as SD according to RECIST had PR according to Choi
criteria. Patients were categorised as PR according to Choi based
on decrease in tumour size X10% (n¼12), decrease in tumour
attenuation X15% (n¼9) or both (n¼15). All six patients with
SD according to Choi criteria had a PFSX12 weeks. Of note, 3 out
of 38 patients defined as SD by RECIST had PD according to Choi
Table 4 Change in tumour size and density for tumour lesions included in the Choi criteria for evaluation of sunitinib treatment in patients with mRCC
Number of eligible
lesions
a
Median pretreatment
values (range)
Median values at first
evaluation (range) Median change (range)
Tumour site N (size/attenuation)
Size
(mm)
Attenuation
(HUs)
Size
(mm)
Attenuation
(HUs)
Size
(%)
Attenuation
(%)
Lung 55/41 25 (15–91) 59 (15–98) 19 (5–110)** 38 (4–81)**  24 ( 71 to +21)  31 ( 92 to +146)
Lymph node 63/56 25 (15–123) 68 (6–118) 25 (9–101) 55 (17–105)**  5(  57 to +59)  14 ( 69 to +183)
Liver 16/16 31 (19–83) 83 (40–96) 32 (16–67) 51 (22–66)**  3(  25 to +45)  38 ( 76 to  5)
Abdominal other
b 26/24 41 (15–140) 65 (33–135) 41 (0–186) 61 (20–112)*  4(  100 to +65)  13 ( 78 to +47)
Thoracic other
c 13/12 27 (17–44) 67 (18–116) 20 (13–55) 53 (21–87)  23 ( 39 to +189)  19 ( 73 to +28)
Total number of lesions 173/149 26 (15–140) 66 (6–135) 24 (0–186)** 47 (4–112)**  11 ( 100 to +189)  24 ( 92 to +183)
Abbreviation: HU¼Hounsfield unit. *Pp0.05, **Pp0.001 compared to baseline value by the Wilcoxon’s signed-ranks test.
aTumour lesions X15mm at baseline but o15mm
at evaluation were included for the analyses regarding the change in tumour size, but were excluded for the analyses regarding the change in tumour attenuation.
bAbdominal
sites, including local recurrence, adrenal gland, spleen, and peritoneum.
cThoracic sites including pleura, breast, and subcutis.
Figure 2 An example of a renal cell cancer patient on sunitinib treatment in which the lung lesion (arrow) showed a decrease in attenuation at first
evaluation. (A) At baseline, the tumour attenuation was 107 Hounsfield units (HUs) and the longest diameter 48mm. (B) At first evaluation, the tumour
attenuation was 65 HUs ( 39%) and the longest diameter was 39mm ( 19%).
Table 5 PFS and OS of mRCC according to RECIST and Choi criteria
Median PFS
a Median OS
Months (range) Months (range)
Response
Choi criteria Log rank¼16.1,
Po0.001
Log rank¼20.0,
Po0.001
Responders
b (n¼36) 14.5 25.4
Non-responders
c (n¼19) 3.2 10.4
RECIST at first evaluation Log rank¼0.2,
P¼0.685
Log rank¼1.7,
P¼0.191
Responders
b (n¼7) 18.3 27.4
Non-responders
c (n¼48) 9.0 13.2
RECIST at best response Log rank¼11.2,
P¼0.001
Log rank¼13.2,
Po0.001
Responders
b (n¼17) 19.3 31.3
Non-responders
c (n¼38) 7.0 15.3
Clinical benefit
RECIST Log rank¼63.2,
Po0.001
Log rank¼18.8,
Po0.001
Clinical benefit
d (n¼41)
a 12.2 22.3
No clinical benefit
e
(n¼13)
2.6 7.2
Abbreviations: RECIST¼Response Evaluation Criteria in Solid Tumours; PFS¼pro-
gression-free survival; OS¼overall survival.
aFor one patient with stable disease, date
of progressive disease was not available.
bPartial response.
cStable disease+pro-
gressive disease.
dPartial response+stable disease X12 weeks.
eProgressive
disease+stable disease o12 weeks.
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scriteria. These three patients had a PFS412 weeks among whom
was one patient that reached a PFS410 months.
Survival analysis
At first evaluation in patients with PR, Choi criteria had a
significantly better predictive value for PFS and OS (Po0.001 for
both) than RECIST (P¼0.685 and 0.191 respectively) (Table 5;
Figure 3). When best response during treatment was analysed
according to RECIST, the predictive value of RECIST increased for
both PFS and OS (P¼0.001 and o0.001 respectively). For clinical
benefit (PR and SDX12 weeks), the predictive value of RECIST for
PFS and OS was also significant (Po0.001 for both). When the two
Choi criteria were analysed separately, in which patients with new
lesions were categorised as PD, only a 15% decrease in attenuation
was predictive for PFS (P¼0.018; log rank¼5.6) and OS
(P¼0.005; log rank¼7.8).
DISCUSSION
In this study, we evaluated whether the new Choi criteria,
which include changes in tumour attenuation, are of additional
value to predict outcome in mRCC patients treated with sunitinib.
The response rate of 31% as measured by RECIST was comparable
with that reported previously (Motzer et al, 2007), indicating
that the present study is representative for sunitinib treatment in
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Figure 3 Kaplan–Meier curves for progression-free survival and overall survival of patients with metastatic renal cell cancer treated with sunitinib:
responders (—) and non-responders (---) at first evaluation according to Choi criteria (A, B) and the Response Evaluation Criteria in Solid Tumours
(RECIST) (C, D) as well as clinical benefit (partial responseþstable disease X12 weeks) (—) and no clinical benefit (progressive diseaseþstable disease
o12 weeks) (---) at first evaluation by RECIST (E, F).
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smRCC patients. At first evaluation, Choi criteria of PR were
able to define a large population with a long PFS and OS, whereas
RECIST PR only identified seven patients with favourable clinical
outcome. When patients with PR and SDX12 weeks during
treatment were taken into account, the predictive value of RECIST
substantially increased. The latter could have been expected, as
patients with SD at first evaluation are likely to continue sunitinib
treatment and a substantial number will eventually reach a PR or
SDX12 weeks.
During sunitinib treatment, we observed tumour necrosis as
illustrated by a reduction in tumour attenuation with a median
decrease of 24% at first evaluation. The TKI sorafenib can also
induce extensive necrosis (Flaherty, 2007). In comparison with
placebo, sorafenib prolonged PFS in cytokine-pretreated mRCC with
almost 3 months (Escudier et al, 2007), although the complete
response (CR) and PR rates by RECIST were only o1 and 10%
respectively (Escudier et al, 2007). These data suggest that
non-responders by RECIST may have benefited from sorafenib.
Therefore, Choi criteria may also be valuable to early identify
mRCC patients who will have a favourable outcome from
sorafenib treatment. Response evaluation by Choi criteria should
ideally be planned on a fixed day during treatment, i.e. day 28 of
sunitinib administration in the 4 weeks on 2 weeks off schedule
in mRCC. The variability in timing of the first on-treatment CT scan
in this study, however, could not be avoided because of its
retrospective design.
Although Choi criteria could easily be applied on routine
standardised contrast-enhanced CT scans, there were several
limitations in the use of these criteria for evaluation of sunitinib-
induced responses in mRCC. First, a large number of lesions
(22%), especially lung metastases, which could be measured by
RECIST, had to be excluded due to a size o15mm at baseline. As
mRCC patients can have rather small metastases, the reliability of
Choi criteria may decrease when smaller lesions (o15mm)
significantly decrease in size or attenuation, but are ineligible for
assessment. Second, the reliability of Choi criteria may also
decrease when fewer lesions are included for analysis. For example,
a 15% decrease in attenuation in five lesions would be more
reasonable than measured in one single lesion. Third, the
attenuation of heterogeneous lesions may be assessed inaccurately,
as the mean value is calculated in one region of interest in one
slice. Fourth, measurements of relatively hypodense lesions at
baseline may be less reliable, because a 15% decrease in
attenuation is less accurate than measurements in lesions with
higher pretreatment attenuation values. For that reason, use of
absolute change may be more precise than the percent change in
attenuation. Fifth, attenuation measurements are not possible in
lesions with sunitinib-induced cavitations, which was the case in
eight lung lesions (Figure 1). Sixth, although the intra-observer
variability appeared to be rather low, the above-described
limitations of Choi criteria imply a risk of high inter-observer
variability and may even lead to a change in response in an
individual patient. Therefore, mutual agreement on the delineation
method should be achieved between the observers. Last, although
i.v. contrast was administered according to the same scanning
protocol and patients with clear differences in i.v. contrast were
excluded, slightly different phases of scanning at subsequent time
points may lead to incorrect changes in lesion attenuation. In that
respect, it should also be mentioned that sunitinib-induced
changes in cardiac output (Chu et al, 2007) might possibly
influence the distribution of i.v. contrast. In mRCC patients,
administration of i.v. contrast may be harmful in the presence of
an impaired renal function.
The ultimate goal in the palliative treatment of mRCC with
sunitinib is prevention of disease progression combined
with acceptable quality of life. Sunitinib, however, is associated
with a wide range of mild toxicities that can be cumbersome,
and alternative treatments for mRCC, such as sorafenib and
temsirolimus, are readily available. Therefore, surrogate markers
for poor PFS and OS are warranted in patients with SD at first
evaluation. Unfortunately, Choi criteria were not able to identify
patients with clear-cut progression, because three patients defined
as PD had a PFS412 weeks. Compared with RECIST, Choi criteria
may be less optimal for identifying PD, probably due to the X10%
increase vs the X20% increase used by RECIST.
In conclusion, Choi criteria can be easily applied on contrast-
enhanced CT scans of mRCC patients treated with sunitinib, but its
reliability is limited, especially in patients with most lesions
o15mm, a small number of lesions, heterogeneous lesions or
hypodense lesions at baseline. Although Choi criteria had a
significantly better predictive value for PFS and OS than RECIST at
first evaluation in patients with PR, its predictive value for
outcome was similar to that of RECIST at later time points.
Because Choi criteria were not able to early identify patients with
PD, these criteria will not change the management of sunitinib-
treated mRCC patients.
ACKNOWLEDGEMENTS
We thank Henk Smit and Jelle Teertstra for help with retrieval of
CT scans and Corinne N Tillier and Henk Mallo for help with
patient care.
REFERENCES
Baccala Jr A, Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A
(2007) Pathological evidence of necrosis in recurrent renal mass
following treatment with sunitinib. Int J Urol 14: 1095–1097
Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL,
Podoloff DA, Charnsangavej C (2007) We should desist using RECIST, at
least in GIST. J Clin Oncol 25: 1760–1764
Bex A, Van der Veldt AA, Blank C, Van den Eertwegh AJ, Boven E,
Horenblas S, Haanen J (2009) Neoadjuvant sunitinib for surgically
complex advanced renal cell cancer of doubtful resectability: initial
experience with downsizing to reconsider cytoreductive surgery. World J
Urol 27: 533–539
Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR,
Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed
tomography and positron emission tomography in patients with
metastatic gastrointestinal stromal tumor treated at a single institution
with imatinib mesylate: proposal of new computed tomography response
criteria. J Clin Oncol 25: 1753–1759
Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L,
Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris
DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD,
Force T, Chen MH (2007) Cardiotoxicity associated with tyrosine kinase
inhibitor sunitinib. Lancet 370: 2011–2019
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier
S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE,
Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM
(2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J
Med 356: 125–134
Faivre SJ, Raymond E, Douillard J, Boucher E, Lim HY, Kim JS, Lanzalone
S, Lechuga MJ, Sherman L, Cheng A (2007) Assessment of safety and
drug-induced tumor necrosis with sunitinib in patients (pts) with
unresectable hepatocellular carcinoma (HCC). J Clin Oncol (Meeting
Abstracts) 25: 3546
Flaherty KT (2007) Sorafenib in renal cell carcinoma. Clin Cancer Res 13:
747s–752s
Choi response criteria for sunitinib in RCC
AAM van der Veldt et al
808
British Journal of Cancer (2010) 102(5), 803–809 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sH e l g a s o nH H ,M a l l oH A ,D r o o g e n d i j kH ,H a a n e nJ B ,V a nd e rV e l d tA A ,V a n
d e nE e r t w e g hA J ,B o v e nE( 2 0 0 8 )B r a i nm e tastases in patients with renal cell
cancer receiving new targeted treatment. JC l i nO n c o l26: 152–154
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-
alfa as a comparative treatment for clinical trials of new therapies against
advanced renal cell carcinoma. J Clin Oncol 20: 289–296
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O,
Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM,
Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell
carcinoma. N Engl J Med 356: 115–124
Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA,
Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer
CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted
inhibitor of vascular endothelial growth factor receptor and platelet-
derived growth factor receptor, in patients with metastatic renal cell
carcinoma. J Clin Oncol 24: 16–24
Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O,
Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007)
Axitinib treatment in patients with cytokine-refractory metastatic renal-
cell cancer: a phase II study. Lancet Oncol 8: 975–984
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein
L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther
SG (2000) New guidelines to evaluate the response to treatment in solid
tumors. J Natl Cancer Inst 92: 205–216
Van Cruijsen H, Van der Veldt AA, Hoekman K (2008) Tyrosine kinase
inhibitors of VEGF receptors: clinical issues and unanswered questions.
Front Biosci 14: 2248–2268
Van der Veldt AA, Boven E, Helgason HH, Van Wouwe M, Berkhof J, De
Gast G, Mallo H, Tillier CN, Van den Eertwegh AJ, Haanen JB (2008a)
Predictive factors for severe toxicity of sunitinib in unselected patients
with advanced renal cell cancer. Br J Cancer 99: 259–265
Van der Veldt AA, Meijerink MR, Van den Eertwegh AJ, Bex A,
De Gast G, Haanen JB, Boven E (2008b) Sunitinib for treatment of
advanced renal cell cancer: primary tumor response. Clin Cancer Res 14:
2431–2436
Vanel D, Albiter M, Shapeero L, Le Cesne A, Bonvalot S, Le Pechoux C,
Terrier P, Petrow P, Caillet H, Dromain C (2005) Role of computed
tomography in the follow-up of hepatic and peritoneal metastases of
GIST under imatinib mesylate treatment: a prospective study of 54
patients. Eur J Radiol 54: 118–123
Choi response criteria for sunitinib in RCC
AAM van der Veldt et al
809
British Journal of Cancer (2010) 102(5), 803–809 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s